Sana biotechnology announces preclinical data published in science translational medicine showing its hypoimmune pancreatic islet cells evaded allogeneic and autoimmune rejection and controlled type 1 diabetes in preclinical model

Hypoimmune human islet cells normalized glucose in diabetic humanized immunocompetent mouse model and avoided allogeneic and autoimmune rejection by the immune system
SANA Ratings Summary
SANA Quant Ranking